ClinicalTrials.gg
RecruitingNCT05711394Updated Oct 6, 2026

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

A Phase 3 interventional study of Atogepant and Placebo-Matching Atogepant in Episodic Migraine, sponsored by AbbVie. Recruiting at 98 sites in 16 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Oct 6, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Planned enrollment
12th of 21
450 · median 468
Started
2023
with 2 others
Phase 3
15 of 21
3 open now
Registered
14th of 21
by date
Lead sponsor
11 of 21
AbbVie

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 12th largest by planned enrollment, is one of 3 that started in 2023, is one of 15 in phase 3, and was the 14th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17.

Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide.

Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks.

There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

03

Conditions studied

  • Episodic Migraine

Browse trials for

Keywords

  • Episodic Migraine
  • Atogepant
  • QULIPTA
  • AGN-241689
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight is >= 20 kg (44 lbs) and \< 135 kg (298 lbs).
  • History of episodic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD) -3 (2018) for at least 6 months.
  • Participant has to have 4 to 14 migraine days and \< 15 headache days in the 28-day baseline period per eDiary.
  • To be eligible for the PK substudy, participants must be 6 to 11 years of age (inclusive), with a history of migraine (consistent with a diagnosis according to the ICHD-3 [2018]) and per investigator judgment is appropriate to receive preventive treatment for migraine.

Exclusion criteria

Exclusion Criteria:

  • History of migraine brainstem aura, hemiplegic migraine, or retinal migraine as defined by ICHD-3 (2018).
  • Have a current diagnosis of chronic migraine as defined by ICHD-3 (2018).
  • Have a current diagnosis of new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3 (2018).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Open-Label PK Substudy: Atogepant Dose A (6-11 yrs)

    Participants aged 6 to 11 will receive oral tablets of atogepant Dose A to determine appropriate dose for the 6-11 year old group in double-blind treatment period.

    Drug: Atogepant

  • Experimental
    Open-Label PK Substudy: Atogepant Dose B (6-11 yrs)

    Participants aged 6 to 11 will receive oral tablets of atogepant Dose B to determine appropriate dose for the 6-11 year old group in double-blind treatment period.

    Drug: Atogepant

  • Experimental
    Double-Blind Treatment Period: High Dose Atogepant (12-17 yrs)

    Participants aged 12 to 17 will receive oral tablets of high dose atogepant once a day for 12 weeks.

    Drug: Atogepant

  • Placebo comparator
    Double-Blind Treatment Period: Placebo (12-17 yrs)

    Participants aged 12 to 17 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks.

    Drug: Placebo-Matching Atogepant

  • Experimental
    Double-Blind Treatment Period: Low Dose Atogepant (12-17 yrs)

    Participants aged 12 to 17 will receive oral tablets of low dose atogepant once a day for 12 weeks.

    Drug: Atogepant

  • Experimental
    Double-Blind Treatment Period: High Dose Atogepant (6-11 yrs)

    Participants aged 6-11 will receive oral tablets of high dose atogepant once a day for 12 weeks.

    Drug: Atogepant

  • Placebo comparator
    Double-Blind Treatment Period: Placebo (6-11 yrs)

    Participants aged 6 to 11 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks.

    Drug: Placebo-Matching Atogepant

  • Experimental
    Double-Blind Treatment Period: Low Dose Atogepant (6-11 yrs)

    Participants aged 6-11 will receive oral tablets of low dose atogepant once a day for 12 weeks.

    Drug: Atogepant

Interventions

  • Oral Tablet

    Also known as: QULIPTA, AGN-241689

  • DrugPlacebo-Matching Atogepant

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Mean Monthly Migraine Days

    A migraine day is defined as any calendar day on which a migraine occurs as per participant eDiary. Calendar days begin at midnight and last until 11:59 PM.

    Time frame: Baseline (Week 0) through Week 12

  2. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Baseline (Week 0) through Week 16

Secondary outcomes

  1. Change from Baseline in Mean Monthly Headache Days

    A headache day is defined as any calendar day on which headache pain lasting 2 hours or longer occurs unless an acute headache medication (e.g., ibuprofen, triptan) was used after the start of the headache, in which case no minimum duration will be specified. Calendar days begin at midnight and last until 11:59 PM.

    Time frame: Baseline (Week 0) through Week 12

  2. Change from Baseline in Mean Monthly Headache Days of at Least Moderate Severity

    A headache day is defined as any calendar day on which headache pain lasting 2 hours or longer occurs unless an acute headache medication (e.g., ibuprofen, triptan) was used after the start of the headache, in which case no minimum duration will be specified. Calendar days begin at midnight and last until 11:59 PM.

    Time frame: Baseline (Week 0) through Week 12

  3. Change from Baseline in Mean Monthly Acute Medication Use Days

    An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) for the acute treatment of migraine.

    Time frame: Baseline (Week 0) through Week 12

  4. Percentage of Participants who Achieve at least a 50% Reduction in Average of Monthly Migraine Days

    A migraine day is defined as any calendar day on which a migraine occurs as per participant eDiary. Calendar days begin at midnight and last until 11:59 PM.

    Time frame: Baseline (Week 0) to 3 Months

  5. Change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) total score

    The PedsQL is a 23-item measure that evaluates quality of life in four areas of functioning: physical, emotional, social, and school functioning. The PedsQL yields a total quality of life score and two summary scores: Physical Health Summary Score and Psychosocial Health Summary Score.

    Time frame: Baseline (Week 0) through Week 12

  6. Change from baseline in the Pediatric Migraine Disability Assessment (PedMIDAS) total score

    The PedMIDAS scale evaluates the impact of headache on school performance, disability at home and social/sport function. The score is a composite of the total of 6 questions.

    Time frame: Baseline (Week 0) through Week 12

07

Study locations

66 of 98 sites recruiting
  • Rehabilitation & Neurological Services /ID# 248517
    Huntsville, Alabama 35805-4046, United States
    Recruiting
  • The Center for Clinical Trials - Saraland /ID# 271604
    Saraland, Alabama 36571, United States
    Recruiting
  • Preferred Research Partners /ID# 249729
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Preferred Research Partners /ID# 270406
    Little Rock, Arkansas 72211, United States
    Completed

    Not enrolling at this site — choose another above.

  • Advanced Research Center /ID# 251381
    Anaheim, California 92805, United States
    Recruiting
  • Alliance for Research Alliance for Wellness /ID# 248521
    Long Beach, California 90807, United States
    Recruiting
  • Excell Research, Inc /ID# 247532
    Oceanside, California 92056, United States
    Completed

    Not enrolling at this site — choose another above.

  • Lumos Clinical Research Center /ID# 249731
    San Jose, California 95124-4108, United States
    Recruiting
  • Sunwise Clinical Research /ID# 248529
    Walnut Creek, California 94596, United States
    Recruiting
  • Advanced Neurosciences Research, LLC /ID# 247592
    Fort Collins, Colorado 80528, United States
    Completed

    Not enrolling at this site — choose another above.

  • Northwest Florida Clinical Research Group, LLC /ID# 251382
    Gulf Breeze, Florida 32561-4495, United States
    Completed

    Not enrolling at this site — choose another above.

  • Advanced Research Institute of Miami /ID# 248539
    Homestead, Florida 33030-4613, United States
    Completed

    Not enrolling at this site — choose another above.

  • My Preferred Research LLC /ID# 249720
    Miami, Florida 33155, United States
    Recruiting
  • FWD Clinical Research - Spring Hill /ID# 248525
    Spring Hill, Florida 34609-5692, United States
    Completed

    Not enrolling at this site — choose another above.

  • Coastal Georgia Child Neurology /ID# 249733
    Brunswick, Georgia 31520-1601, United States
    Recruiting
    • Site Coordinator · Contact770-376-7912
  • Deaconess Clinic - Gateway Health Center /ID# 247589
    Newburgh, Indiana 47630, United States
    Recruiting
    • Site Coordinator · Contact812-474-7184
  • College Park Family Care Center Overland Park /ID# 249734
    Overland Park, Kansas 66210-2761, United States
    Completed

    Not enrolling at this site — choose another above.

  • Michigan Headache & Neurological Institute (MHNI) /ID# 247468
    Ann Arbor, Michigan 48104-5131, United States
    Recruiting
    • Site Coordinator · Contact734-677-6000
  • Proven Endpoints LLC /ID# 258066
    Ridgeland, Mississippi 39157, United States
    Recruiting
    • Site Coordinator · Contact601-790-1811
  • Cognitive Clinical Trials (CCT) - Papillion /ID# 248536
    Papillion, Nebraska 68046-4131, United States
    Completed

    Not enrolling at this site — choose another above.

  • Goryeb Childrens Hospital /ID# 249724
    Morristown, New Jersey 07960, United States
    Recruiting
  • Dent Neurologic Institute - Amherst /ID# 248534
    Amherst, New York 14226, United States
    Recruiting
    • Site Coordinator · Contact716-558-5670
  • Modern Migraine MD /ID# 258074
    New York, New York 10001, United States
    Completed

    Not enrolling at this site — choose another above.

  • Headache Wellness Center /ID# 251018
    Greensboro, North Carolina 27405, United States
    Recruiting
  • Patient Priority Clinical Sites, LLC /ID# 247535
    Cincinnati, Ohio 45215-2123, United States
    Recruiting
    • Site Coordinator · Contact513-791-7760
  • Cincinnati Childrens Hospital Medical Center /ID# 258070
    Cincinnati, Ohio 45229, United States
    Recruiting
  • CincyScience /ID# 249726
    West Chester, Ohio 45069, United States
    Completed

    Not enrolling at this site — choose another above.

  • Lynn Institute of Oklahoma City /ID# 247600
    Oklahoma City, Oklahoma 73112, United States
    Completed

    Not enrolling at this site — choose another above.

  • Children's Hospital of Philadelphia - Main /ID# 258071
    Philadelphia, Pennsylvania 19104-4319, United States
    Recruiting
  • Le Bonheur Children's Hospital /ID# 261084
    Memphis, Tennessee 38103, United States
    Completed

    Not enrolling at this site — choose another above.

  • Access Clinical Trials, Inc. /ID# 248532
    Nashville, Tennessee 37203, United States
    Recruiting
  • UT Health Austin at Dell Children's Neurology Clinic /ID# 264082
    Austin, Texas 78723-3079, United States
    Recruiting
  • FutureSearch Trials of Neurology /ID# 247470
    Austin, Texas 78731, United States
    Completed

    Not enrolling at this site — choose another above.

  • 3A Research - East El Paso /ID# 248516
    El Paso, Texas 79925-7945, United States
    Completed

    Not enrolling at this site — choose another above.

  • Earle Research /ID# 248501
    Friendswood, Texas 77546, United States
    Recruiting
    • Site Coordinator · Contact281-218-8080
  • Family Psychiatry of The Woodlands /ID# 249727
    The Woodlands, Texas 77381, United States
    Completed

    Not enrolling at this site — choose another above.

  • ClinPoint Trials /ID# 248540
    Waxahachie, Texas 75165-1430, United States
    Recruiting
  • Pantheon Clinical Research /ID# 251601
    Bountiful, Utah 84010-4968, United States
    Recruiting
  • Alpine Research Organization - Clinton /ID# 276497
    Clinton, Utah 84015, United States
    Recruiting
  • Highland Clinical Research /ID# 247590
    Salt Lake City, Utah 84124, United States
    Recruiting
  • Office of Maria Ona /ID# 249738
    Franklin, Virginia 23851, United States
    Recruiting
  • Core Clinical Research /ID# 249721
    Everett, Washington 98201, United States
    Completed

    Not enrolling at this site — choose another above.

  • Uza /Id# 247339
    Edegem, Antwerpen 2650, Belgium
    Recruiting
  • Algemeen Ziekenhuis Sint-Jan Brugge /ID# 247201
    Bruges, West-Vlaanderen 8000, Belgium
    Recruiting
  • Stollery Children's Hospital /ID# 249672
    Edmonton, Alberta T6G 2B7, Canada
    Recruiting
  • London Health Sciences Center- University Hospital /ID# 252979
    London, Ontario N6A 5W9, Canada
    Recruiting
  • McGill University Health Centre - Glen Site /ID# 247271
    Montreal, Quebec H4A 3J1, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Herlev Hospital /ID# 247724
    Herlev, Capital Region 2730, Denmark
    Recruiting
  • Regionshospitalet Godstrup /ID# 247902
    Herning, Central Jutland 7400, Denmark
    Recruiting
    • Site Coordinator · Contact+45 50935730
  • Aalborg Sygehus Nord /ID# 247428
    Aalborg, North Denmark 9000, Denmark
    Completed

    Not enrolling at this site — choose another above.

  • CHU Amiens-Picardie Site Sud /ID# 248833
    Amiens, Somme 80054, France
    Completed

    Not enrolling at this site — choose another above.

  • Centre Hosp Intercommunal de Creteil /ID# 248832
    Créteil, Val-de-Marne 94000, France
    Completed

    Not enrolling at this site — choose another above.

  • CHU Toulouse - Hôpital des enfants /ID# 247553
    Toulouse, 31059, France
    Completed

    Not enrolling at this site — choose another above.

  • MIND Clinic /ID# 248687
    Budapest, 1024, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Semmelweis Egyetem /ID# 248360
    Budapest, 1085, Hungary
    Recruiting
  • Shamir Medical Center /ID# 256857
    Beer Ya'akov, Central District 70300, Israel
    Recruiting
  • Hillel Yaffe Medical Center /ID# 246747
    Hadera, Haifa District 38100, Israel
    Completed

    Not enrolling at this site — choose another above.

  • The Chaim Sheba Medical Center /ID# 246746
    Ramat Gan, Tel Aviv 5265601, Israel
    Recruiting
  • Tel Aviv Sourasky Medical Center /ID# 247466
    Tel Aviv, Tel Aviv 6423906, Israel
    Recruiting
  • Bnai Zion Medical Center /ID# 247469
    Haifa, 3339419, Israel
    Recruiting
  • Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 247581
    Milan, Milano 20133, Italy
    Recruiting
  • Ospedale Pediatrico Bambino Gesu /ID# 247647
    Rome, Roma 00165, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 247638
    Palermo, 90127, Italy
    Recruiting
  • Konan Medical Center /ID# 254457
    Kobe, Hyōgo 658-0064, Japan
    Recruiting
  • Yamaguchi Clinic /ID# 254753
    Nishinomiya, Hyōgo 663-8204, Japan
    Recruiting
  • Umenotsuji Clinic /ID# 254453
    Kochi, Kochi 780-8011, Japan
    Recruiting
  • Sendai Headache and Neurology Clinic Medical Corporation /ID# 254211
    Sendai, Miyagi 982-0014, Japan
    Recruiting
  • Tominaga Clinic - Osaka /ID# 254450
    Osaka, Osaka 556-0015, Japan
    Recruiting
  • Tokyo Medical University Hospital /ID# 254459
    Shinjuku-ku, Tokyo 160-0023, Japan
    Recruiting
  • Tatsuoka Neurology Clinic /ID# 254455
    Kyoto, 600-8811, Japan
    Recruiting
  • Canisius-Wilhelmina Ziekenhuis /ID# 253065
    Nijmegen, Gelderland 6532 SZ, Netherlands
    Recruiting
  • HagaZiekenhuis /ID# 247318
    The Hague, South Holland 2545 AA, Netherlands
    Recruiting
  • ZorgSaam Zorggroep Zeeuws-Vlaanderen /ID# 247301
    Terneuzen, Zeeland 4535 PA, Netherlands
    Recruiting
  • Clinical Research Center Medic-R /ID# 247383
    Poznan, Greater Poland Voivodeship 60-848, Poland
    Recruiting
  • Athleticomed Sp. z o.o /ID# 248789
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-752, Poland
    Recruiting
  • Specjalistyczne Gabinety Sp. z o.o. /ID# 247384
    Krakow, Lesser Poland Voivodeship 30-539, Poland
    Recruiting
  • Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej /ID# 247382
    Lublin, Lublin Voivodeship 20-582, Poland
    Recruiting
  • Oha-Med Sp. Z O.O /ID# 248614
    Warsaw, Masovian Voivodeship 01-018, Poland
    Recruiting
  • MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak /ID# 247381
    Wroclaw, 52-210, Poland
    Recruiting
  • Clinical Research Investigator Group /ID# 261254
    Bayamón, 00960, Puerto Rico
    Completed

    Not enrolling at this site — choose another above.

  • Dr. Samuel Sanchez PSC /ID# 248495
    Caguas, 00727, Puerto Rico
    Completed

    Not enrolling at this site — choose another above.

  • Puerto Rico Health Institute /ID# 249741
    Dorado, 00646, Puerto Rico
    Recruiting
    • Site Coordinator · Contact787-797-1049
  • Caribbean Medical Research Center Headlands /ID# 251634
    San Juan, 00918-3501, Puerto Rico
    Completed

    Not enrolling at this site — choose another above.

  • PRCCI Clinical Research Center /ID# 262726
    San Juan, 00927, Puerto Rico
    Completed

    Not enrolling at this site — choose another above.

  • Spitalul Clinic de Copii Dr. Victor Gomoiu /ID# 248431
    Bucharest, Bucharest 022102, Romania
    Completed

    Not enrolling at this site — choose another above.

  • Spitalul Clinic de Urgenta pentru Copii Cluj Napoca /ID# 248595
    Cluj-Napoca, Cluj 400012, Romania
    Completed

    Not enrolling at this site — choose another above.

  • Delta Health Care S.R.L /ID# 248130
    Bucharest, 014146, Romania
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Universitario Vall de Hebron /ID# 247967
    Barcelona, 08035, Spain
    Recruiting
  • Hospital Clinico San Carlos /ID# 249267
    Madrid, 28040, Spain
    Recruiting
  • Hospital Universitario 12 de Octubre /ID# 275578
    Madrid, 28041, Spain
    Recruiting
  • Hospital Universitario Virgen del Rocio /ID# 248632
    Seville, 41013, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Universitario y Politecnico La Fe /ID# 247969
    Valencia, 46026, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Sodersjukhuset /ID# 248279
    Stockholm, Stockholm County 118 83, Sweden
    Recruiting
  • Vastra Gotealandsregionen Regionhalsan /ID# 248277
    Mölnlycke, 435 30, Sweden
    Recruiting
  • Great Ormond Street Children's Hospital /ID# 262933
    London, Greater London WC1N 3HZ, United Kingdom
    Recruiting
  • Medway NHS Foundation Trust /ID# 249065
    Gillingham, Kent ME7 5NY, United Kingdom
    Recruiting
  • NHS Grampian /ID# 249067
    Aberdeen, AB15 6RE, United Kingdom
    Recruiting
  • Stepping Hill Hospital-Stockport NHS foundation trust /ID# 261121
    Stockport, SK2 7JE, United Kingdom
    Recruiting
08

References and documents

Publications

  • Shin L, Mentz O, Gelfand AA, de Prado BM, Shapiro H, Oh A, Onifade OO, Saunders J, Raj N, Szperka CL. Gepants for headache prevention in children and adolescents: A multicenter chart review study. Headache. 2026 Jan;66(1):239-248. doi: 10.1111/head.15087. Epub 2025 Nov 14. PubMed 41235617 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Mar 2028, 58 months after the start.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 58 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 3, 2023
StartActual
May 1, 2023
Primary completionEst.
Mar 2028
CompletionEst.
May 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now completed)
Show 3 sites
  • Aalborg Sygehus Nord /ID# 247428 · Aalborg, DenmarkRecruiting→Completed
  • Caribbean Medical Research Center Headlands /ID# 251634 · San Juan, Puerto RicoRecruiting→Completed
  • Lynn Institute of Oklahoma City /ID# 247600 · Oklahoma City, United StatesRecruiting→Completed
across 2 updates, Oct 5, 2026 – Oct 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Lynn Institute of Oklahoma City /ID# 247600 · Oklahoma City, United StatesContact removed •••8839
Oct 6, 2026
Show all 2 updates
  1. Oct 6, 2026
    Lynn Institute of Oklahoma City /ID# 247600 is now Completed
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Lynn Institute of Oklahoma City /ID# 247600 · Oklahoma City, United StatesContact removed •••8839
  2. Oct 5, 2026
    2 sites changed recruiting status (2 now completed)
    Show 2 sites
    • Aalborg Sygehus Nord /ID# 247428 · Aalborg, DenmarkRecruiting→Completed
    • Caribbean Medical Research Center Headlands /ID# 251634 · San Juan, Puerto RicoRecruiting→Completed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05711394
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 3, 2023
Start date
May 1, 2023
Primary completion
Mar 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion